Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-05-10
2005-05-10
Davis, Zinna Northington (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S317000, C514S318000, C514S321000, C514S326000, C514S336000, C514S364000, C514S365000, C514S374000, C514S376000, C514S382000, C514S389000, C514S392000, C514S422000, C514S444000, C549S060000, C546S194000, C546S197000, C546S207000, C546S209000, C546S210000, C546S211000, C546S213000, C546S281700, C546S282100, C544S335000
Reexamination Certificate
active
06890928
ABSTRACT:
This invention is directed to aromatic sulfone hydroxamic acids (including hydroxamates) and salts thereof that, inter alia, inhibit matrix metalloproteinase (also known as “matrix metalloprotease” or “MMP”) activity and/or aggrecanase activity. This invention also is directed to a prevention or treatment method that comprises administering such a compound or salt in an MMP-inhibiting and/or aggrecanase-inhibiting effective amount to an animal, particularly a mammal having (or disposed to having) a pathological condition associated with MMP and/or aggrecanase activity.
REFERENCES:
patent: 4595700 (1986-06-01), Donald et al.
patent: 5932595 (1999-08-01), Bender et al.
patent: 6013649 (2000-01-01), Freskos et al.
patent: 6300514 (2001-10-01), Takahashi et al.
patent: 6541489 (2003-04-01), Barta et al.
patent: 20030073718 (2003-04-01), Barta et al.
patent: 0 266 182 (1988-05-01), None
patent: 0 606 046 (1994-07-01), None
patent: 0 780 386 (1997-06-01), None
patent: 0 930 067 (1999-07-01), None
patent: 1 081 137 (2001-03-01), None
patent: 4-338331 (1992-11-01), None
patent: WO 9005719 (1990-05-01), None
patent: WO 9320047 (1993-10-01), None
patent: WO 9402466 (1994-02-01), None
patent: WO 9424140 (1994-10-01), None
patent: WO 9509841 (1995-04-01), None
patent: WO 9513289 (1995-05-01), None
patent: WO 9529892 (1995-11-01), None
patent: WO 9606074 (1996-02-01), None
patent: WO 9611209 (1996-04-01), None
patent: WO 9720824 (1997-06-01), None
patent: WO 9724117 (1997-07-01), None
patent: WO 9837877 (1998-09-01), None
patent: WO 9838163 (1998-09-01), None
patent: WO 9909000 (1999-02-01), None
patent: WO 9925687 (1999-05-01), None
patent: WO 9942436 (1999-08-01), None
patent: WO 0046221 (2000-08-01), None
patent: WO 0050396 (2000-08-01), None
patent: WO 0059874 (2000-10-01), None
patent: WO 0069821 (2000-11-01), None
Brown, “Synthetic Inhibitors of Matrix Metalloproteinases”,Matrix Metalloproteinases, pp. 243-261 (Academic Press, San Diego, CA, Eds. Park, W.C., & Mecham, R.P., 1998).
Dack, et al., “Preparation of N-hydroxytetrahydropyridylsulfonylacetamides and related compounds as matrix metalloprotease inhibitors,” CA 131:44740 (1999).
Denis, et al., “Matrix metalloproteinase inhibitors: Present achievements and future prospects,”Invest. New Drugs, 15:175-185 (1997).
Freije, et al., “Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas,”J. Biol. Chem., 269(24), pp. 16766-16773 (1994).
Gearing, et al., “Processing of tumour necrosis factor-α precursor by metalloproteinases”,Nature, 370:555-557 (1994).
Gu, et al., “S-Nitrosylation of Matrix Metalloproteinases: Signaling Pathway to Neuronal Cell Death,”Science, 297, 1186-1190 (2002).
Hughes, et al., “Monoclonal antibodies that specifically recognize neoepitope sequences generated by ‘aggrecanase’ and matrix metalloproteinase cleavage of agrecan: application to catabolism in situ and in vitro,”Biochem. J., 305, 799-804 (1995).
Kenyon, et al., “A Model of Angiogenesis in the Mouse Cornea,”Investigative Ophthalmology&Visual Science, vol. 37, No. 8:1625-32 (Jul. 1996).
Knight, et al., “A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinase,”FEBS Lett., 296(3):263-266 (1992).
Kuzmic, et al., “High-throughput screening of enzyme inhibitor: simultaneous determination of tright-binding inhibition constants and enzyme concentration,”Anal. Biochem., 286, 45-50 (2000).
Luckow, et al., “Insect Cell Expression Technology”,Protein Enginerring: Principles and Practice, pp. 183-218 (John Wiley & Sons, Inc., New York, NY, Edited by J.L. Cleland et al., 1996).
Luckow, et al., “Efficient generation of infectious recombinant baculoviruses by site-specific transposon-mediated insertion of foreign genes into a baculovirus genome propagated inEscherihia coli,” J. Virol., 67(8):4566-4579 (1993).
McClure, et al., “Matrix metalloprotease (MMP)-13 selective inhibitors for treatment of arthritis deformans and other MMP-related diseases,” CA 131:125454 (1999) [CA Plus Accession No. 1999:468334].
McGeehan, et al., “Regulation of tumour necrosis factor-α processing by a metalloproteinase inhibitor,”Nature, 370:558-561 (1994).
Mitchell, et al., “Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage,”J. Clin. Invest., 97(3):761-768 (1996).
Rasmussen, et al., “Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat,”Pharmacol. Ther., 75(1):69-75 (1997).
Reboul, et al., “The new collagenase, collagnease-3, is expressed and synthesized by human chondrocytes but not by synoviocytes,”J. Clin. Invest., 97(9):2011-2019 (1996).
Schwartz, et al., “Synthetic inhibitors of bacterial and mammalian interstitial collagenases,”Prog. in Med. Chem., 29:271-334 (1992).
Tang, “ADAMTS: a novel family of extracellular matrix proteases,”Int'l J. Biochem. Cell Biol., 33, 33-44 (2001).
Woessner, “The Matrix Metalloproteinase Family,”Matrix Metalloproteinases, pp. 1-14 (Academic Press, San Diego, CA, Eds. Parks, W.C. & Mecham, R.P., 1998).
Barta Thomas E.
Becker Daniel P.
Bedell Louis J.
Boehm Terri L.
Carroll Jeffrey N.
Davis Zinna Northington
Harness Dickey & Pierce PLC
Pharmacia Corporation
LandOfFree
Aromatic sulfone hydroxamic acids and their use as protease... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aromatic sulfone hydroxamic acids and their use as protease..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aromatic sulfone hydroxamic acids and their use as protease... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3455519